BACKGROUND: The symptoms of women with premenstrual syndrome improve in response to suppression of ovarian function, although these women have no evidence of ovarian dysfunction. We undertook a study to determine the role of estrogen and progesterone in this syndrome. METHODS: We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with the premenstrual syndrome. Ten women whose symptoms improved during leuprolide treatment were given estradiol and progesterone in a double-blind, crossover design, each for four weeks, during continued leuprolide administration. Women without premenstrual syndrome (normal women) participated in a similar protocol. Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales. RESULTS: The 10 women with premenstrual syndrome who were givenleuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo. The 10 women with premenstrual syndrome who were givenleuprolide plus estradiol or progesterone had a significant recurrence of symptoms, but no changes in mood occurred in 15 normal women who received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone during continued leuprolide administration. CONCLUSIONS: In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.
RCT Entities:
BACKGROUND: The symptoms of women with premenstrual syndrome improve in response to suppression of ovarian function, although these women have no evidence of ovarian dysfunction. We undertook a study to determine the role of estrogen and progesterone in this syndrome. METHODS: We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with the premenstrual syndrome. Ten women whose symptoms improved during leuprolide treatment were given estradiol and progesterone in a double-blind, crossover design, each for four weeks, during continued leuprolide administration. Women without premenstrual syndrome (normal women) participated in a similar protocol. Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales. RESULTS: The 10 women with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo. The 10 women with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a significant recurrence of symptoms, but no changes in mood occurred in 15 normal women who received the same regimen or in 5 women with premenstrual syndrome who were given placebo hormone during continued leuprolide administration. CONCLUSIONS: In women with premenstrual syndrome, the occurrence of symptoms represents an abnormal response to normal hormonal changes.
Authors: Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt Journal: Neuropsychologia Date: 2015-12-21 Impact factor: 3.139
Authors: Zengjian Wang; Xiaoyun Wang; Jian Liu; Jun Chen; Xian Liu; Guangning Nie; Kristen Jorgenson; Ki Cheul Sohn; Ruiwang Huang; Ming Liu; Bo Liu; Jian Kong Journal: J Psychiatr Res Date: 2016-09-16 Impact factor: 4.791
Authors: Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow Journal: Am J Psychiatry Date: 2016-08-13 Impact factor: 18.112
Authors: Kristina M Deligiannidis; Elif M Sikoglu; Scott A Shaffer; Blaise Frederick; Abby E Svenson; Andre Kopoyan; Chelsea A Kosma; Anthony J Rothschild; Constance M Moore Journal: J Psychiatr Res Date: 2013-03-15 Impact factor: 4.791